Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Phathom Pharmaceuticals (PHAT) EBIAT (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed EBIAT for 5 consecutive years, with -$30.4 million as the latest value for Q1 2026.

  • For Q1 2026, EBIAT rose 67.8% year-over-year to -$30.4 million; the TTM value through Mar 2026 reached -$157.3 million, up 54.51%, while the annual FY2025 figure was -$221.2 million, 33.82% up from the prior year.
  • EBIAT hit -$30.4 million in Q1 2026 for Phathom Pharmaceuticals, down from -$21.1 million in the prior quarter.
  • Across five years, EBIAT topped out at -$21.1 million in Q4 2025 and bottomed at -$94.3 million in Q1 2025.
  • Average EBIAT over 5 years is -$58.0 million, with a median of -$51.1 million recorded in 2022.
  • Year-over-year, EBIAT crashed 123.23% in 2024 and then surged 71.59% in 2025.
  • Phathom Pharmaceuticals' EBIAT stood at -$55.0 million in 2022, then plummeted by 44.55% to -$79.6 million in 2023, then increased by 6.43% to -$74.5 million in 2024, then soared by 71.59% to -$21.1 million in 2025, then plummeted by 43.6% to -$30.4 million in 2026.
  • According to Business Quant data, EBIAT over the past three periods came in at -$30.4 million, -$21.1 million, and -$30.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.